Insulet Corporation (PODD)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $10.58B
Last updated: Nov 17, 2026 at 11:06 AM ET
Insulet Corporation (PODD) Earnings: Report Dates and Results
Insulet (PODD) is expected to report earnings on Feb 16, 2027. In the quarter ended Sep 30, 2026, Insulet reported EPS of $1.99, above the $1.59 estimate. It beat the EPS estimate in each of the last 9 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PODD has an expected report date of Feb 16, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 16.8% above the $1.55 reported for the quarter ended Dec 31, 2025.
PODD Earnings Call
The latest PODD earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 38 quarters below that had an estimate, PODD beat 26, missed 10 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $842.00M, up 19.2% from $706.30M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $1.99 | $1.59 | $1.50 - $1.66 | +25.16% | Beat | +60.5% | 23 | 1 up, 2 down | Nov 4, 2026 | $842.00M |
| Jun 30, 2026 | $1.66 | $1.44 | $1.36 - $1.55 | +15.28% | Beat | +41.9% | 22 | 0 up, 1 down | Aug 5, 2026 | $801.70M |
| Mar 31, 2026 | $1.42 | $1.19 | $1.06 - $1.29 | +19.33% | Beat | +39.2% | 21 | 0 up, 2 down | May 6, 2026 | $761.70M |
| Dec 31, 2025 | $1.55 | $1.48 | $1.32 - $1.86 | +4.73% | Beat | +34.8% | 20 | 0 up, 1 down | Feb 18, 2026 | $783.70M |
| Sep 30, 2025 | $1.24 | $1.15 | $1.01 - $1.28 | +7.83% | Beat | +37.8% | 20 | 1 up, 1 down | Nov 6, 2025 | $706.30M |
| Jun 30, 2025 | $1.17 | $0.93 | $0.78 - $1.13 | +25.81% | Beat | +112.7% | 20 | 0 up, 1 down | Aug 7, 2025 | $649.10M |
| Mar 31, 2025 | $1.02 | $0.79 | $0.63 - $1.16 | +29.11% | Beat | +39.7% | 18 | 2 up, 0 down | May 8, 2025 | $569.00M |
| Dec 31, 2024 | $1.15 | $1.02 | $0.93 - $1.17 | +12.63% | Beat | -17.9% | 15 | 7 up, 4 down | Feb 20, 2025 | $597.50M |
| Sep 30, 2024 | $0.90 | $0.76 | $0.70 - $0.86 | +18.42% | Beat | +26.8% | 17 | 0 up, 0 down | Nov 7, 2024 | $543.90M |
| Jun 30, 2024 | $0.55 | $0.56 | $0.46 - $0.73 | -1.79% | Miss | +44.7% | 19 | 1 up, 0 down | Aug 8, 2024 | $488.50M |
| Mar 31, 2024 | $0.73 | $0.39 | $0.28 - $0.61 | +87.18% | Beat | +217.4% | 16 | 1 up, 0 down | May 9, 2024 | $441.70M |
| Dec 31, 2023 | $1.40 | $0.66 | $0.50 - $0.82 | +112.12% | Beat | +483.3% | 16 | 0 up, 0 down | Feb 22, 2024 | $509.80M |
| Sep 30, 2023 | $0.71 | $0.41 | $0.26 - $0.55 | +73.17% | Beat | +73.2% | 18 | 1 up, 0 down | Nov 2, 2023 | $432.70M |
| Jun 30, 2023 | $0.38 | $0.26 | $0.13 - $0.36 | +46.15% | Beat | N/A | 18 | 0 up, 0 down | Aug 8, 2023 | $396.50M |
| Mar 31, 2023 | $0.23 | $0.10 | $0.03 - $0.25 | +130.00% | Beat | -42.5% | 15 | 0 up, 0 down | May 4, 2023 | $358.10M |
| Dec 31, 2022 | $0.24 | $0.21 | $0.04 - $0.42 | +14.29% | Beat | -42.9% | 17 | 0 up, 0 down | Feb 23, 2023 | $369.70M |
| Sep 30, 2022 | $0.41 | $0.14 | $0.07 - $0.21 | +192.86% | Beat | +105.0% | 15 | 0 up, 2 down | Nov 3, 2022 | $340.80M |
| Jun 30, 2022 | -$0.08 | $0.23 | N/A | -134.78% | Miss | -153.3% | N/A | 0 up, 1 down | Aug 4, 2022 | $299.40M |
| Mar 31, 2022 | $0.40 | $0.24 | $0.11 - $0.29 | +66.67% | Beat | N/A | 15 | 0 up, 1 down | May 5, 2022 | $295.40M |
| Dec 31, 2021 | $0.42 | $0.32 | $0.22 - $0.44 | +31.25% | Beat | N/A | 17 | 0 up, 0 down | Feb 23, 2022 | $307.70M |
| Sep 30, 2021 | $0.20 | $0.25 | $0.11 - $0.39 | -20.00% | Miss | +17.6% | 21 | N/A | Nov 4, 2021 | $275.60M |
| Jun 30, 2021 | $0.15 | $0.14 | $0.05 - $0.24 | +7.14% | Beat | -31.8% | 21 | N/A | Aug 5, 2021 | $263.20M |
| Mar 31, 2021 | Not reported | $0.09 | -$0.08 - $0.22 | N/A | Not reported | N/A | 19 | N/A | May 6, 2021 | $252.30M |
| Dec 31, 2020 | -$0.04 | -$0.04 | -$0.19 - $0.15 | 0.00% | In line | -140.0% | 18 | N/A | Feb 23, 2021 | $246.10M |
| Sep 30, 2020 | $0.17 | $0.08 | -$0.04 - $0.25 | +112.50% | Beat | +88.9% | 20 | N/A | Nov 4, 2020 | $234.00M |
| Jun 30, 2020 | $0.22 | $0.01 | -$0.08 - $0.16 | N/A | N/A | +1000.0% | 20 | N/A | Aug 6, 2020 | $226.30M |
| Mar 31, 2020 | -$0.03 | -$0.01 | -$0.10 - $0.11 | -200.00% | Miss | -142.9% | 19 | N/A | May 7, 2020 | $198.00M |
| Dec 31, 2019 | $0.10 | $0.12 | -$0.02 - $0.27 | -16.67% | Miss | -37.5% | 17 | N/A | Feb 25, 2020 | $209.40M |
| Sep 30, 2019 | $0.09 | $0.04 | -$0.11 - $0.11 | +125.00% | Beat | +200.0% | 16 | N/A | Nov 5, 2019 | $192.10M |
| Jun 30, 2019 | $0.02 | $0.03 | -$0.14 - $0.10 | -33.33% | Miss | N/A | 18 | N/A | Aug 5, 2019 | $177.10M |
| Mar 31, 2019 | $0.07 | $0.01 | -$0.04 - $0.15 | +600.00% | Beat | N/A | 18 | N/A | May 2, 2019 | $159.60M |
| Dec 31, 2018 | $0.16 | $0.07 | $0.02 - $0.16 | +128.57% | Beat | N/A | 18 | N/A | Feb 25, 2019 | $164.88M |
| Sep 30, 2018 | $0.03 | $0.03 | -$0.23 - $0.06 | 0.00% | In line | N/A | 17 | N/A | Nov 1, 2018 | $151.08M |
| Jun 30, 2018 | -$0.03 | -$0.13 | -$0.23 - -$0.07 | +76.92% | Beat | N/A | 17 | N/A | Aug 2, 2018 | $124.26M |
| Mar 31, 2018 | -$0.11 | -$0.18 | -$0.28 - -$0.08 | +38.89% | Beat | N/A | 17 | N/A | May 3, 2018 | $123.58M |
| Dec 31, 2017 | -$0.12 | -$0.08 | -$0.15 - -$0.01 | -50.00% | Miss | N/A | 16 | N/A | Feb 21, 2018 | $130.56M |
| Sep 30, 2017 | -$0.04 | -$0.10 | -$0.16 - -$0.03 | +60.00% | Beat | N/A | 17 | N/A | Nov 2, 2017 | $121.78M |
| Jun 30, 2017 | -$0.13 | -$0.12 | -$0.17 - -$0.04 | -8.33% | Miss | N/A | 16 | N/A | Aug 3, 2017 | $109.76M |
| Mar 31, 2017 | -$0.17 | -$0.15 | N/A | -13.33% | Miss | N/A | N/A | N/A | May 8, 2017 | $101.71M |
| Dec 31, 2016 | -$0.16 | -$0.05 | N/A | -220.00% | Miss | N/A | N/A | N/A | Feb 27, 2017 | $103.58M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $4.98, up 49.5% from the year before. It was -$0.44 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $4.98 | +49.5% |
| Dec 31, 2024 | $3.33 | +22.4% |
| Dec 31, 2023 | $2.72 | +180.4% |
| Dec 31, 2022 | $0.97 | +26.0% |
| Dec 31, 2021 | $0.77 | +140.6% |
| Dec 31, 2020 | $0.32 | N/A |
| Dec 31, 2019 | $0.28 | +460.0% |
| Dec 31, 2018 | $0.05 | N/A |
| Dec 31, 2017 | -$0.46 | N/A |
| Dec 31, 2016 | -$0.44 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,600 words across 13 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,648 | 13 | |
| 2026Q2 | Jun 30, 2026 | 6,702 | 14 | |
| 2026Q1 | Mar 31, 2026 | 6,734 | 14 | |
| 2025Q4 | Dec 31, 2025 | 8,575 | 14 | |
| 2025Q3 | Sep 30, 2025 | 7,500 | 18 | |
| 2025Q2 | Jun 30, 2025 | 8,093 | 20 | |
| 2025Q1 | Mar 31, 2025 | 6,613 | 18 | |
| 2024Q4 | Dec 31, 2024 | 9,205 | 19 |
2026Q3 Earnings Call
Opening remarks
Clare Trachtman Vice President, Investor Relations Good morning, and welcome to our third quarter 2026 earnings call. Joining me today are Ashley A. McEvoy, President and Chief Executive Officer, and Flavia H. Pease, Chief Financial Officer. On the call this morning, we will be discussing Insulet's third quarter results along with our financial outlook for the fourth quarter and full year 2026. With that, let me start our prepared remarks by reminding everyone that certain statements, including comments regarding our financial outlook, the anticipated impact of our strategic actions, the potential impact of various regulatory and operational matters, and the macroeconomic environment on our results of operations, contain forward-looking statements that involve risks and uncertainties. And, of course, our actual results could differ materially from our current expectations. Please refer to today's press release and our SEC filings for more detail concerning factors that could cause actual results to differ materially. In addition, on today's call, non-GAAP financial measures will be used to help investors understand Insulet's ongoing business performance, including adjusted operating income, adjusted EPS, adjusted tax rate, and constant-currency revenue, which is revenue growth excluding the effect of foreign exchange. A reconciliation of certain non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in the accompanying investor presentation and available in our earnings release issued this morning, both of which are available on our website. Additionally, unless otherwise stated, all financial commentary regarding dollar and percentage changes will be on a year-over-year reported basis, with the exception of revenue growth rates, which will be on a year-over-year constant-currency basis. During the Q&A session this morning, Ashley, Flavia, and I will be available to address any questions. Now I would like to turn the call over to Ashley. Ashley?
Ashley A. McEvoy President and CEO Good morning, everyone, and thanks for joining us to discuss our third quarter results. Our teams delivered a strong quarter, with U.S. performance in our guidance range and international performance that exceeded our plans. As we near the end of the year, we have narrowed our total company full-year outlook to the top end of our prior range to reflect this strength. Throughout the quarter, we continued advancing our strategic priorities: strengthening our commercial capabilities and execution, accelerating innovation, and expanding the category by increasing access and building relationships with prescribers. Importantly, we made progress against the type 2 action plan we laid out on our quarter 2 call. We are pleased with our progress in the quarter, and I want to take a step back and provide some broader perspective. Insulet has a strong leadership position in one of the largest, fastest-growing, and most underpenetrated segments in med tech.
Frequently Asked Questions About PODD
When is Insulet's next earnings date?
Insulet's next earnings report is expected for Feb 16, 2027.
Did PODD beat earnings estimates last quarter?
Yes. Insulet reported EPS of $1.99 for the quarter ended Sep 30, 2026, above the $1.59 estimate, a 25.16% surprise.
What EPS do analysts expect from PODD next quarter?
The consensus EPS estimate for Insulet for the quarter ending Dec 31, 2026 is $1.81 from 27 analysts, with estimates from $1.57 to $2.08.
How often does PODD beat earnings estimates?
Insulet beat the EPS estimate in each of the last 9 quarters, with an average surprise of +17.59%.
PODD pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors